Evommune (EVMN) Retained Earnings (2024 - 2026)

Evommune's (EVMN) quarterly Retained Earnings came in at -$242.8 million in Q1 2026, down 9.8% on a QoQ basis from -$221.1 million in Q4 2025.

Evommune (EVMN) Retained Earnings (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Retained Earnings data on file, last reported at -$242.8 million in Q1 2026.

On a quarterly basis, Retained Earnings changed N/A year-over-year to -$242.8 million in Q1 2026; TTM through Mar 2026 was -$242.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$221.1 million, down 45.24% from the prior year.
Retained Earnings for Q1 2026 stood at -$242.8 million, down from -$221.1 million in the prior quarter.
Over the last five years, Retained Earnings for EVMN reached as high as -$152.2 million in Q4 2024 and fell as low as -$242.8 million in Q1 2026.
Historically, Retained Earnings has averaged -$202.2 million across 3 years, with a median of -$206.9 million in 2025.
On a YoY basis, Retained Earnings climbed as much as 45.24% in 2025 and fell as far as 45.24% in 2025.
Year by year, Retained Earnings stood at -$152.2 million in 2024, then sank by 45.24% to -$221.1 million in 2025, then dropped by 9.8% to -$242.8 million in 2026.
Per Business Quant data, the three most recent Retained Earnings figures were -$242.8 million in Q1 2026, -$221.1 million in Q4 2025, and -$192.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Retained Earnings (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-527.87 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-27.89 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	12.91 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	115.82 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	14.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	11.90 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-622,000.00
10	Evommune	381.48 Mn	170.02 Mn	-	-242.76 Mn

Download Data